Women’s health diagnostics company Evvy has raised $40 million in an oversubscribed Series B funding round to advance and validate its artificial intelligence-powered diagnostic and care models.

The round was led by Catalio Capital Management, with participation from Rethink Impact, Muse Capital and Alumni Ventures. Existing investors, including Amboy Street Ventures, Ingeborg, Foreground Capital and Flywheel Ventures, also participated.

Founded in 2021 by Priyanka Jain, Laine Bruzek and Pita Navarro, Evvy has developed a clinical-grade dataset focused on the vaginal microbiome and its links to women’s health outcomes. Its machine learning platform, EvvyAI, analyses biological data to support diagnostic development and treatment decisions.

The company said it has served more than 100,000 patients and 3,000 practitioners through at-home testing, personalised treatment recommendations and ongoing biomarker monitoring.

The funding will primarily be used to support clinical validation of EvvyAI-powered diagnostic models and expand distribution through medical professionals and partner organisations. Fertility will be an initial focus area, as the company seeks to address cases involving vaginal symptoms or fertility issues that remain unexplained through standard testing.

Evvy will also continue its research partnership with US Fertility to investigate the relationship between the vaginal microbiome and reproductive health.

“Women hear ‘unexplained’ constantly—unexplained infertility, unexplained recurrence, unexplained pain. It’s stated like a diagnosis, when it really just means medicine wasn’t built to measure female biology,” said Priyanka Jain, Co-Founder, Evvy.

“Evvy is building the evidence, infrastructure, and partnerships needed to make precision, data-driven care the standard for women’s health,” she added.